MUC1 and cancer: After confirming the binding ability of the constructed recombinant anti‐MUC1 nanobody to MUC1, efficacy and functionality of the nanobody against variety of cancer cell lines was evaluated with MTT and flow cytometry‐based apoptosis assays.